Roivant Sciences Balance Sheet
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences financial position
At the end of fiscal 2025, Roivant Sciences reported total assets of $5.71 billion, up 5.0% from a year earlier against total liabilities of $416.3 million. Shareholders' equity stood at $4.53 billion, or 79.3% of assets. The company held $1.42 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 18.37, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences balance sheet (annual)
| Fiscal year (USD) | FY 20252026-03-31 | FY 20242025-03-31 | FY 20232024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20202021-03-31 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.42B | 2.72B | 6.49B | 1.68B | 2.06B | 2.06B |
| Short-Term Investments | 2.87B | 2.17B | 0 | — | — | — |
| Receivables | — | — | 3.99M | 30.38M | 3.88M | 11.22M |
| Inventory | — | — | 35.25M | 2.76M | 0 | — |
| Total Current Assets | 5.17B | 5.00B | 6.73B | 1.80B | 2.15B | 2.19B |
| Property, Plant & Equipment | 11.99M | 12.06M | 15.32M | 39.09M | 25.91M | 14.75M |
| Intangible Assets | — | — | 137.84M | 144.88M | 0 | — |
| Long-Term Investments | — | — | — | — | 0 | 100.56M |
| Total Assets | 5.71B | 5.44B | 7.22B | 2.39B | 2.59B | 2.59B |
| Accounts Payable | 18.00M | 23.69M | 14.03M | 37.83M | 34.58M | 20.55M |
| Short-Term Debt | — | — | 12.00M | 40.72M | 0 | 0 |
| Total Current Liabilities | 281.24M | 149.41M | 266.76M | 272.45M | 184.37M | 218.96M |
| Long-Term Debt | — | — | 430.59M | 375.51M | 210.03M | 170.28M |
| Total Liabilities | 416.27M | 249.74M | 773.95M | 782.02M | 523.70M | 527.69M |
| Shareholders' Equity | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B | 1.80B |
| Retained Earnings | -501.81M | 116.06M | 576.17M | -3.77B | -2.76B | -1.92B |
| Total Debt | — | — | 442.59M | 416.24M | 210.03M | 170.28M |
| Net Cash (Debt) | 4.29B | 4.89B | 6.05B | 1.26B | 1.85B | 1.88B |
| Shares Outstanding | 720.35M | 695.94M | 806.68M | 760.14M | 694.98M | 651.58M |
This table shows 6 annual periods of Roivant Sciences's balance sheet, from FY 2025 back to FY 2020, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ROIV's reporting calendar. What is a balance sheet?